ARTICLES BY LOUIS

• What’s A “Biopharma CDMO”?

  11/15/2020

  In part two of my exclusive interview with Phlow Corporation's CEO Dr. Eric Edwards, we turn our attention to biopharma business models and CDMO partnerships.

• You Don’t Know Phlow: The Backstory Of A Misread Biopharma Start-Up

  11/9/2020

  No biopharma start-up has been as misconstrued, hastily judged in strategy and capability, or even labeled “political.” Now Phlow Corporation’s CEO Eric Edwards sets the record straight in an exclusive interview.

• Where Have All The “Early Amgens” Gone? To Tech Transfers, Every One

  11/1/2020

  “My opinion is not theoretical. It reflects having seen it in action at Amgen, from 1986 to 1995, with the launching of Epogen & Neupogen.” Like biopharma’s Nietzsche, Mark Witcher wants us to slay outdated beliefs – “tech transfer” being a prime target.

• The Witcher Way: Can We “Eliminate” Tech Transfer?

  10/18/2020

  “You can call me a revolutionary, if you like,” responds Mark Witcher upon my comment he is. His thesis on the elimination of "tech transfer" is detailed, and provocative. But is it practical? Readers will make the ultimate judgment.

• Tech Transfer, Self-Esteem, And A Fitting Facility

  10/14/2020

  “This is akin to making the process for the tech transfer as efficient as you are trying to make the process to produce the actual material.” Part 2 of our “dissertation” on the mental and physical state of tech transfer in drug development and manufacturing outsourcing.

• A Real Dissertation On Tech Transfer

  10/10/2020

  A biopharma professional is earning a degree in tech transfer. Literally. Here’s some of what he’s learned, including the four thorns in the side of those transferring drug development and manufacturing projects to CDMOs.

• Outsourcing Trend Of The Year? The CDMO Synergy Sprint

  10/4/2020

  Two more CDMOs – this time in Germany – announce their best-in-breed alliance. What are these partnerships all about? Will this trend benefit readers looking for the best outsourcing outcomes? 

• Hello From The Other Side: Advice On Drug Development Outsourcing

  10/1/2020

  Some colleagues worked at CDMOs before joining your biopharma organization. Given the opportunity, they can guide you to enlightened vendor management and improved outsourcing outcomes.

• Today’s Biotech Start-Up: Experienced Leaders, Wise Investors

  9/27/2020

  Biopharma start-ups and their investors have grown up. “They come in with a different mindset,” says Sesha Neervannan, Tarsus Pharmaceuticals, still enthusiastic about his own career move from bigger pharma to biotech.

• CDMOs Should Take On More Project Ownership

  9/17/2020

  "I want to hire CDMOs that take shared accountability and more ownership of the projects, products, and of the relationship," says a biopharma executive. You should, too. Here's how.